Last Update: Wednesday, July 23, 2014

Taking the Brakes off the Immune System to Fight Deadly Cancers PDF Print E-mail
Written by San Fernando Valley Sun   
Thursday, 05 June 2014 04:11

Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) are reporting exciting treatment milestones for patients with deadly cancers who are being treated with an experimental drug called MK- 3475. The drug is an antibody that targets a protein expressed by immune cells called PD-1.

In the body, PD-1 acts as an immune checkpoint, turning down the immune system's T cells that otherwise would attack cancer cells as invaders. MK-3475 takes the brakes off the immune system and allows T cells to identify and attack cancer cells.

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to MK-3475 for unresectable or metastatic melanoma in May 2013 under its Accelerated Approval program.

In UCLA clinical trials, doctors are seeing unprecedented treatment success with MK- 3475 in two types of cancer that have historically had very low survival rates. The first is metastatic melanoma, a malignant skin cancer that spreads (metastasizes) aggressively beyond the initial tumor to invade other vital organs, such as brain, lungs or liver. The other is lung cancer, the cause of the highest number of cancer deaths in the U.S. year after year.

Metastatic Melanoma

Dr. Antoni Ribas, professor of hematology-oncology and JCCC member, led what is probably the largest phase 1 study ever conducted in cancer, with 411 patients who had metastatic melanoma. In a disease with an average five-year survival rate of less than five percent, the one-year overall survival rate was 69 percent for all patient subgroups. Response to the drug, meaning those patients whose tumors shrank, was continuing in 88 percent of patients at the time the study was analyzed, after an average 12-month follow-up.

Tumors responded in patients from all the different dose regimens and in various patient subgroups, including those whose cancers had worsened after having received the drug ipilimumab. There are currently no treatment options with proven activity for those patients.

"We are seeing unprecedented durable responses with this drug," Ribas said. "MK-3475 is working in patients that had not been treated, as well as those who had been given ipilimumab and other therapies. These are early data, but response rates of this magnitude in such a large sample, with only four percent of patients discontinuing because of drug-related side effects, indicate the importance of moving forward quickly with this drug."


Overall, 34 percent of patients had responses to MK- 3475, including 40 percent not treated with ipilimumab and 28 percent whose cancer worsened despite ipilimumab treatment. Treatment-related side effects were mild and reversible for the most part. Eight percent of patients had serious side effects.

Non-Small Cell Lung Cancer (NSCLC)

Dr. Edward Garon, assistant professor of hematology-oncology and JCCC member led a cohort of 217 metastatic nonsmall cell lung cancer (NSCLC) patients whose disease worsened during or after at least one prior therapy as part of the same MK-3475 study. This was the largest report of lung cancer patients being treated with this approach of inhibiting PD-1.

The usual standard therapy for patients in this situation is chemotherapy with a single drug. After one prior therapy, an overall survival of approximately six to nine months is usual, with less than 10 percent of patients responding to therapy, and even then responses are generally of short duration. Outcomes are typically worse in patients who have received two or more therapies, as was often the case in this study.

For the majority of lung cancer patients whose tumors expressed PD-L1, a target of PD-1, 23 percent had a response to this therapy, and the responses were often durable.

"We are very excited about the preliminary results we are seeing with MK-3475 in these advanced lung cancer patients," Garon said. "It is a very well tolerated drug, so the benefits are enhanced by the fact that it generally has very little negative effect on patient quality of life. We are conducting additional trials with MK- 3475, and based on our work, we hope the drug will soon be available to patients throughout the world."

Share
 






Team members care for thousands of the region's sickest children with heart conditions, including fetuses, newborns, infants, children, adolescents, and adult, long-term patients with pediatric cardiovascular conditions. At Children's families experience coordinated, next-generation care, delivered by a compassionate, multidisciplinary team of leaders in the pediatric cardiology field. One of the largest pediatric cardiovascular programs in the region. Studies have shown that high volumes are associated with high quality and better outcomes, because experience is a major factor in quality of care. Wort was traditionally prescribed in parts of Europe for depression (in addition to use as a general-purpose tea), and Chinese medicine developed elaborate lists of herbs and preparations. With the scientific revolution in Europe and the United States, the use of traditional herbal remedies fell out of favor with the mainstream medical establishment, although a few people continued to use and maintain knowledge of traditional European herblore. In the early 20th century, scientists began reassessing this rejection of traditional herbs in medicine. Vorzüge eines intakten und lebendigen Gemeinschaftslebens bewahren. Dafür sorgen nicht zuletzt gut 120 lokale Vereine. Als wichtiger Faktor im Kulturleben haben sich die zahlreichen Museen und einige Kunstgalerien erwiesen. Descriptive and quantitative transcriptome analyses are important for interpreting the functional elements of the genome and revealing the molecular constituents of cells and tissues. It is known that sperm function can be affected by ASG proteins, including the processes of capacitation and the acrosome reaction, as well as canadian pharmacy accutane sperm motility, DNA integrity and interaction with the oocyte. BSPs (bovine seminal plasma protein, unigene 64,588 and unigene 69,768), fertilin (unigene 17,270 and unigene 27,136), ACE (Angiotensin converting enzyme, unigene 7,164 and unigene 21,069), GPX5 (glutathione peroxidase, epididymal secretory glutathione peroxidase, unigene15860), Spermadhesin-1 (Acidic seminal fluid protein, aSFP). The reproduction-related transcripts identified in the ASG and testis transcritptomes in E. This interaction of PDC-109 with the sperm cell membrane results in an efflux of cholesterol and choline phospholipids, that appears to be important for capacitation. The main changes in spermatozoa that occur during epididymal maturation are the ability to move, recognize and bind to the ZP, and to fuse with the plasma membrane of the oocyte.. Oct 2004, Adelaide, Australia. Ziaian T, Augostinos, M. Relationship Between Acculturation and Mental Well-being Among Young Persian Women Living in Australia. Paper presented at the Educational Research conference, 18th November 2004, Adelaide, Australia. Ziaian T, Stress Management: an introduction of holistic coping strategies. A Four day Course for the higher degree students. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer. Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B. Prophylactic removal of nevi without clinically worrisome characteristics is not recommended. The reasons for this are practical: many individuals in these families have a large number of nevi, and complete removal of them all is not feasible, since new atypical nevi continue to develop. In addition, individuals with increased susceptibility to melanoma may have cancer arise de novo, without a precursor lesion such as a nevus. The disadvantages of screening include the limitations of available noninvasive testing methods and the risks associated with invasive screening procedures. ERCP is the gold standard for http://www.jerseycanada.com/jerseyatlantic/fnt/ultramer.php identifying early cancers and precancerous lesions in the pancreas..